Electronic Monitoring Device for HIV
(A-TEAM Trial)
Trial Summary
What is the purpose of this trial?
The investigators propose using an electronic adherence device that is basically a pill container that can alert when it is not opened at a scheduled time. The investigators will use this device to alert the medication user at the time when medication is supposed to be taken if the device did not get opened and a pre-identified social support person or case manager when 2 or 7 consecutive days of nonadherence are detected, respectively. The investigators call our approach "A-Team" (Antiretroviral Therapy Electronic Adherence Monitoring). The aims of this application are to determine the acceptability and feasibility of real-time adherence monitoring in support persons and case managers of African American Men who have sex with Men and to test this approach for these men in a 6-month randomized controlled trial among 54 of these men living with HIV and measure ART adherence and viral suppression (the primary outcome).
Will I have to stop taking my current medications?
The trial does not specify whether you need to stop taking your current medications. However, since it involves monitoring adherence to your existing HIV medication, it seems likely that you will continue your current treatment.
What data supports the effectiveness of the A-TEAM treatment for HIV?
Research shows that using electronic monitoring devices can improve adherence to antiretroviral therapy, with one study noting an increase in adherence from 84% to 93% when real-time monitoring and follow-up were used. Additionally, technology-driven interventions, like electronic reminder devices, have been shown to significantly improve adherence in several studies, although more rigorous research is needed to confirm these findings.12345
Is the Electronic Monitoring Device for HIV safe for humans?
What makes the A-TEAM treatment unique for HIV?
The A-TEAM treatment is unique because it uses electronic monitoring devices to track when patients take their HIV medication, allowing for real-time interventions if doses are missed. This approach aims to improve adherence to antiretroviral therapy, which is crucial for controlling the virus and preventing progression to AIDS.3571011
Research Team
Mark Dworkin, MD
Principal Investigator
University of Illinois Chicago
Eligibility Criteria
This trial is for African American men who have sex with men, over 18 years old, living with HIV and struggling with medication adherence. They must be on antiretroviral therapy (ART) for at least six months, own a cell phone, and have either a detectable viral load or self-reported poor adherence. A supportive case manager or person from their social circle also needs to participate.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the A-TEAM intervention with real-time electronic adherence monitoring for 6 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- A-TEAM
A-TEAM is already approved in United States for the following indications:
- HIV treatment adherence support
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Illinois at Chicago
Lead Sponsor
Massachusetts General Hospital
Collaborator